Drug Interactions between methscopolamine / phenylephrine and Viberzi
This report displays the potential drug interactions for the following 2 drugs:
- methscopolamine/phenylephrine
- Viberzi (eluxadoline)
Interactions between your drugs
phenylephrine methscopolamine
Applies to: methscopolamine / phenylephrine and methscopolamine / phenylephrine
Methscopolamine may increase the effects of phenylephrine on your blood pressure and heart rate. Before receiving these medications, you should let your doctor know if you have high blood pressure or heart disease. You may not be able to use one or both of these medications, or you may need closer monitoring by your doctor in order to use these medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
methscopolamine eluxadoline
Applies to: methscopolamine / phenylephrine and Viberzi (eluxadoline)
Using eluxadoline together with methscopolamine may increase the risk and/or severity of constipation and other gastrointestinal complications. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. You should stop taking eluxadoline and contact your doctor if you develop constipation that lasts more than 4 days. Always seek advice from a health care professional before taking any over-the-counter medications for diarrhea. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Drug and food interactions
eluxadoline food
Applies to: Viberzi (eluxadoline)
Eluxadoline should be taken twice daily with food. You should avoid excessive alcohol use during treatment with eluxadoline. Consumption of more than 3 alcoholic beverages per day while taking eluxadoline may increase the risk of pancreatitis, or inflammation of the pancreas. Talk to your doctor if you have any questions or concerns. You should seek immediate medical attention if you experience potential symptoms of pancreatitis such as persistent nausea, vomiting, abdominal tenderness, and upper abdominal pain, especially that which is made worse after eating or radiates to the back or shoulders. Symptoms of pancreatitis usually go away when treatment with eluxadoline is stopped.
methscopolamine food
Applies to: methscopolamine / phenylephrine
Ask your doctor before using methscopolamine together with ethanol. Use alcohol cautiously. Alcohol may increase drowsiness and dizziness while you are taking methscopolamine. You should be warned not to exceed recommended dosages and to avoid activities requiring mental alertness. If your doctor prescribes these medications together, you may need a dose adjustment to safely take this combination. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
phenylephrine food
Applies to: methscopolamine / phenylephrine
Consumer information for this interaction is not currently available.
MONITOR: Coadministration of two or more sympathomimetic agents may increase the risk of adverse effects such as nervousness, irritability, and increased heart rate. Central nervous system (CNS) stimulants, particularly amphetamines, can potentiate the adrenergic response to vasopressors and other sympathomimetic agents. Additive increases in blood pressure and heart rate may occur due to enhanced peripheral sympathetic activity.
MANAGEMENT: Caution is advised if two or more sympathomimetic agents are coadministered. Pulse and blood pressure should be closely monitored.
References
- Rosenblatt JE, Lake CR, van Kammen DP, Ziegler MG, Bunney WE Jr "Interactions of amphetamine, pimozide, and lithium on plasma norepineophrine and dopamine-beta-hydroxylase in schizophrenic patients." Psychiatry Res 1 (1979): 45-52
- Cavanaugh JH, Griffith JD, Oates JA "Effect of amphetamine on the pressor response to tyramine: formation of p-hydroxynorephedrine from amphetamine in man." Clin Pharmacol Ther 11 (1970): 656
- "Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc PROD (2001):
- "Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals PROD (2001):
- "Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals PROD (2001):
- "Product Information. Focalin (dexmethylphenidate)." Mikart Inc (2001):
- "Product Information. Strattera (atomoxetine)." Lilly, Eli and Company (2002):
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.